GLAXOSMITHKLINE PHARMA A/S: Financial statements 2023
CVR: 27394019
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
GLAXOSMITHKLINE PHARMA A/S (CVR 27394019) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 474,477,000 and a net result of DKK 12,003,000 compared with DKK 11,068,000 the year before. That is an increase of 7.8% compared with the year before. The profit margin was 2.5%. Equity in the 2023 report amounted to DKK 37,889,000. The solvency ratio was 32.3%. The company had 72 employees in the financial year.
- Revenue
- DKK 474,477,000
- Gross Profit
- DKK 119,781,000
- Profit/Loss
- DKK 12,003,000
- Equity
- DKK 37,889,000
- Total Assets
- DKK 117,324,000
- Employees
- 72
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 474.5M | 119.8M | 12M | 37.9M | 72 |
| 2022 | 440.3M | 126.2M | 11.1M | 36.9M | 68 |
| 2021 | 445.9M | 111.6M | 9M | 34.8M | 66 |
| 2020 | 441.7M | 120.3M | 12.3M | 37.8M | 62 |
| 2019 | 417.4M | 114.3M | 11.1M | 35.5M | 68 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of November 1, 2023, Tetiana Luczkiw has left the board of directors of GLAXOSMITHKLINE PHARMA A/S.
GLAXOSMITHKLINE PHARMA A/S has published its annual report for 2022. Revenue came to DKK 440,283,000, and the net result was DKK 11,068,000.
As of May 1, 2023, Hemal Depan Malde has joined the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of May 1, 2023, Helle Ann Hellberg has joined the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of May 1, 2023, Dominika M Wiktor-Brown has joined the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of May 1, 2023, David Mattheus Fredericus Rademakers has left the board of directors of GLAXOSMITHKLINE PHARMA A/S.
As of May 1, 2023, Dominika M Wiktor-Brown is registered as director of GLAXOSMITHKLINE PHARMA A/S.
As of May 1, 2023, David Mattheus Fredericus Rademakers has stepped down as adm. dir. of GLAXOSMITHKLINE PHARMA A/S.
About GLAXOSMITHKLINE PHARMA A/S
GLAXOSMITHKLINE PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1968. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named GLAXO DANMARK A/S and GLAXO WELLCOME A/S. The management consists of Diederik Maarten Eijsvogel. The board consists of Luciano Alves de Andrade (chair), Alastair William Jones, Diederik Maarten Eijsvogel and Helle Ann Hellberg. The company is owned by Setfirst Limited. The company has 83 employees (2026). In 2025, the company reported revenue of DKK 580,769,000 and a net result of DKK 13,123,000 compared with DKK 12,240,000 the year before. Equity in the 2025 report amounted to DKK 39,017,000.